GSK PLC GSK shares rose 1.06% to £13.34 Tuesday, on what proved to be an all-around dismal trading session for the stock ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.01% of ...

Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...

Shares of GSK plc (NYSE:GSK – Get Free Report) have been given an average rating of “Moderate Buy” by the ten research firms ...

Shares of GSK PLC GSK inched down 0.75% to £13.20 Monday, on what proved to be an all-around grim trading session for the ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

Analysts at Zacks Research reduced their Q1 2026 EPS estimates for shares of GSK in a research note issued to investors on ...

智通财经APP获悉，日前，映恩生物 (Duality Biologics)宣布与GSK (GSK.US)已就一项抗体偶联药物 (ADC)DB-1324达成独家授权协议。根据协议，GSK将获得该ADC药物的全球 (不包括中国大陆、香港地区和澳门地区)独家授权，以推进该疗法的研发与商业化进程。

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

GSK GSK stock has declined 20.2% in the past three months compared with a decrease of 12.3% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the ...

GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK announced that its B7-H3-targeted antibody-drug conjugate, GSK’227, has received ...